TWI680128B - 二氫吡咯並吡啶衍生物 - Google Patents

二氫吡咯並吡啶衍生物 Download PDF

Info

Publication number
TWI680128B
TWI680128B TW107120944A TW107120944A TWI680128B TW I680128 B TWI680128 B TW I680128B TW 107120944 A TW107120944 A TW 107120944A TW 107120944 A TW107120944 A TW 107120944A TW I680128 B TWI680128 B TW I680128B
Authority
TW
Taiwan
Prior art keywords
pyridin
pyrrolo
dihydro
group
dimethyl
Prior art date
Application number
TW107120944A
Other languages
English (en)
Chinese (zh)
Other versions
TW201920166A (zh
Inventor
伊莉莎白 貝克
Elizabeth Mary BECK
麥可 布羅尼
Michael Aaron Brodney
馬休 布朗
Matthew Frank Brown
克里斯多夫 布特勒
Christopher Ryan BUTLER
亞當 吉爾伯特
Adam Matthew Gilbert
艾瑞克 拉奇佩利
Erik Alphie LACHAPELLE
羅拉 麥艾里斯特
Laura Ann Mcallister
丹尼爾 尤西羅
Daniel Paul UCCELLO
磊 張
Lei Zhang
Original Assignee
美商輝瑞股份有限公司
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商輝瑞股份有限公司, Pfizer Inc. filed Critical 美商輝瑞股份有限公司
Publication of TW201920166A publication Critical patent/TW201920166A/zh
Application granted granted Critical
Publication of TWI680128B publication Critical patent/TWI680128B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW107120944A 2017-06-22 2018-06-19 二氫吡咯並吡啶衍生物 TWI680128B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523306P 2017-06-22 2017-06-22
US62/523,306 2017-06-22

Publications (2)

Publication Number Publication Date
TW201920166A TW201920166A (zh) 2019-06-01
TWI680128B true TWI680128B (zh) 2019-12-21

Family

ID=62981279

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107120944A TWI680128B (zh) 2017-06-22 2018-06-19 二氫吡咯並吡啶衍生物

Country Status (19)

Country Link
US (1) US11198692B2 (enExample)
EP (1) EP3642202B1 (enExample)
JP (1) JP7263266B2 (enExample)
KR (1) KR20200013783A (enExample)
CN (1) CN110944998B (enExample)
AU (1) AU2018287787A1 (enExample)
BR (1) BR112019026955A2 (enExample)
CA (1) CA3066986A1 (enExample)
DK (1) DK3642202T3 (enExample)
ES (1) ES2937236T3 (enExample)
FI (1) FI3642202T3 (enExample)
HU (1) HUE060914T2 (enExample)
IL (1) IL271290B2 (enExample)
MX (1) MX2019015371A (enExample)
PL (1) PL3642202T3 (enExample)
PT (1) PT3642202T (enExample)
SG (1) SG11201913014YA (enExample)
TW (1) TWI680128B (enExample)
WO (1) WO2018234953A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4061813B1 (en) * 2019-11-22 2025-06-04 F. Hoffmann-La Roche AG Pyrrolidine derivatives
CN112174869B (zh) * 2020-10-12 2023-04-25 蔡霈 N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途
JP2025534061A (ja) * 2022-10-28 2025-10-09 紐欧申医薬（上海）有限公司 窒素含有複素環化合物、その薬学的に許容される塩及びその調製方法と使用
KR20250121123A (ko) 2022-12-16 2025-08-11 카루나 세러퓨틱스 인코포레이티드 치환된 테트라히드로피롤로-피리디논 화합물 및 의학적 병태를 치료하는 데 있어서의 이의 용도
WO2024130065A1 (en) * 2022-12-16 2024-06-20 Karuna Therapeutics, Inc. Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions
JP2025541362A (ja) * 2022-12-16 2025-12-18 カルナ セラピューティクス，インコーポレイテッド 置換テトラヒドロピロロ－ピリジノン化合物及び医学的状態の治療におけるその使用
CN120641421A (zh) * 2022-12-16 2025-09-12 卡鲁娜治疗学有限公司 经取代的二氢吡咯并[3,4-d]嘧啶化合物及其在治疗医学病状中的用途
KR20250130620A (ko) * 2022-12-16 2025-09-02 카루나 세러퓨틱스 인코포레이티드 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도
WO2024260386A1 (zh) * 2023-06-20 2024-12-26 西藏海思科制药有限公司 毒蕈碱m4受体激动剂及其用途
WO2025055970A1 (zh) * 2023-09-15 2025-03-20 江苏恩华药业股份有限公司 氮杂环丁烷衍生物、其制备方法及其医药用途
WO2025083630A1 (en) 2023-10-19 2025-04-24 Suven Life Sciences Limited Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025099660A1 (en) 2023-11-10 2025-05-15 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025103475A1 (zh) * 2023-11-17 2025-05-22 上海翰森生物医药科技有限公司 杂环羰基类衍生物调节剂、其制备方法和应用
WO2025122809A1 (en) * 2023-12-07 2025-06-12 Acadia Pharmaceuticals Inc. M4 positive allosteric modulators
WO2025131049A1 (en) * 2023-12-21 2025-06-26 Ignis Therapeutics (Suzhou) Limited Dihydro-pyrrolo-pyridine derivatives and uses thereof
WO2025134078A1 (en) 2023-12-22 2025-06-26 Suven Life Sciences Limited Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123612A (en) * 1964-03-03 Z-acylated z
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2767191A (en) 1953-12-31 1956-10-16 American Cyanamid Co Dihydropyrrolo-pyridines
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2000109481A (ja) * 1999-10-13 2000-04-18 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体含有医薬
SI1257584T2 (sl) 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
CA2427661C (en) 2000-11-03 2013-05-28 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
MX2007004794A (es) 2004-10-25 2007-07-09 Lilly Co Eli Tienopiridinas como potenciadores alostericos del receptor muscarinico m4.
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
DK1848694T3 (da) * 2005-02-07 2010-01-25 Hoffmann La Roche Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8227475B2 (en) 2005-05-12 2012-07-24 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
CA2676456C (en) 2007-01-22 2012-03-27 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
AR083855A1 (es) 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
WO2013126856A1 (en) 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2015027214A1 (en) * 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
DK3478679T3 (da) 2016-07-01 2021-06-21 Pfizer 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123612A (en) * 1964-03-03 Z-acylated z
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators

Also Published As

Publication number Publication date
US20200262833A1 (en) 2020-08-20
CA3066986A1 (en) 2018-12-27
WO2018234953A1 (en) 2018-12-27
NZ760036A (en) 2025-05-30
AU2018287787A1 (en) 2020-01-16
FI3642202T3 (fi) 2023-03-01
IL271290B1 (en) 2023-07-01
ES2937236T3 (es) 2023-03-27
DK3642202T3 (da) 2023-01-30
HUE060914T2 (hu) 2023-04-28
CN110944998A (zh) 2020-03-31
PL3642202T3 (pl) 2023-03-13
JP2020524687A (ja) 2020-08-20
IL271290A (en) 2020-01-30
KR20200013783A (ko) 2020-02-07
US11198692B2 (en) 2021-12-14
SG11201913014YA (en) 2020-01-30
BR112019026955A2 (pt) 2020-06-30
CN110944998B (zh) 2022-08-16
IL271290B2 (en) 2023-11-01
EP3642202A1 (en) 2020-04-29
JP7263266B2 (ja) 2023-04-24
MX2019015371A (es) 2020-07-20
TW201920166A (zh) 2019-06-01
EP3642202B1 (en) 2022-11-02
PT3642202T (pt) 2023-02-02

Similar Documents

Publication Publication Date Title
TWI680128B (zh) 二氫吡咯並吡啶衍生物
US11905284B2 (en) 5,7-dihydro-pyrrolo-pyridine derivatives
US12398119B2 (en) Piperazine azaspiro derivatives
JP6505023B2 (ja) Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP6506833B2 (ja) イミダゾピリダジン化合物
JP6425717B2 (ja) ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン
HK40099374A (en) Piperazine azaspiro derivatives
HK40058715A (en) 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders
HK40027664B (en) Dihydro-pyrrolo-pyridine derivatives
HK40027664A (en) Dihydro-pyrrolo-pyridine derivatives
HK40027521A (en) Dihydro-pyrrolo-pyridine derivatives
HK40045213B (en) Piperazine azaspiro derivaves
HK40008377B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases